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Abstract
Background: Human Papillomavirus (HPV) vaccination, intended for young women aged 11–14 years old, has been
introduced in Switzerland in 2007. Ten years after its introduction, only a few studies have explored the reasons
associated with uptake and non-uptake of the vaccination. Our objective was to identify the sociodemographic
characteristics of a population of vaccinated and unvaccinated undergraduate healthcare female students, to define
the reasons of non-uptake of vaccination, and compare our findings with those found in other Swiss cantons.
Methods: Between January and November 2017, women studying in Health Sciences School and Medical School
in Geneva, aged 18–31 years old, were recruited in a large trial assessing HPV prevalence. As part of a smaller,
observational study nested in this larger trial, women were invited to complete a questionnaire. Self-reported HPV
vaccination uptake or non-uptake, as well as knowledge and attitude about HPV vaccination were assessed. T-Test
and Chi square test were used to compare characteristics of vaccinated and unvaccinated women.
Results: Overall, 409 women were recruited in the study. The majority of them (69.1%) reported having been
vaccinated for HPV, while 30.9% of them had never received any dose of the HPV vaccine. The only factor
associated with a higher vaccination rate was the participants’ origin, as women from Geneva were more
represented in the vaccinated group than women from other Swiss regions or countries. Unvaccinated women
were more likely to consider HPV vaccination as less important than the vaccinated ones (50.4% vs 3.5% p < 0.001).
Conclusion: Although no typical profile can be established in this studied population of unvaccinated women, a
lack of information was a major reason of non-uptake of vaccination among the study participants. An effort by
health authorities and carefully designed messages are essential to increase the population’s awareness over
cervical cancer and its prevention.
Trial registration: The trial was registered under cliniclatrials.gov with the identifier: NCT03474211.
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Background
Human Papillomavirus (HPV) is responsible for the
most prevalent sexually transmitted infection worldwide,
which represents a major public health challenge [1]. It
is estimated that up to 70% of the sexually active
population will be infected with HPV at least once in
their life [2]. The highest infection rate is found among
16–25-year-old women. While up to 70% of HPV infec-
tions are spontaneously cleared after a few months [3],
the persistence of the virus is responsible for the
development of cervical cancer, which is associated to
HPV in nearly 100% of cases [4]. Cervical cancer is the
fifth most common cancer among women aged 20–49
years living in Switzerland [5]. Every year, Switzerland
counts as many as 250 cervical cancer and 5′000
cervical precancerous lesion diagnoses [6].
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HPV vaccination represents a fundamental primary
prevention measure for the development of cervical can-
cer. The currently available vaccines in Switzerland are
Gardasil® and Cervarix®, both of which protect against
HPV genotypes 16 and 18, which are responsible for the
development of cervical cancer in over 70% of cases [7].
Gardasil®, which has been available on the market since
2007, also covers against genotypes 6 and 11, which are
mostly responsible for the development of genital
condylomas [8].
The Swiss recommendations for HPV vaccination were
first published in 2007, advising the vaccination for all
females between the ages of 11 and 14 years while also
recommending a catch-up vaccination for women aged
15 to 19 years [9]. The aim of such primary prevention
measure is to cover over 80% of the target population.
Such recommendations, however, were implemented by
each federal canton individually. Such individualized
implementation has resulted in disparities in the cam-
paigns and, therefore, in vaccination rates across the
country (from 17 to 75% of the targeted population
in 2014) [10].
In the Canton of Geneva, the first HPV vaccination
campaign tookplace in September 2008. The greatest
asset of the campaign in Geneva is the strong involve-
ment of school health services, such as the Service de
L’Enfant et de la Jeunesse (SSJ) in public schools, which
inform families and offer vaccination to all female school
children aged 11–19 years old. According to a study on
HPV vaccination carried out 4 years after the first cam-
paign, the majority of 13–14 year-old girls had been vac-
cinated through the SSJ, thus proving its efficiency [11].
Despite this institutional effort, however, the targeted
coverage rate of 80% has yet to be reached. Only a few
studies have been carried out with the aim of under-
standing the reasons for non-vaccination in Switzerland.
Moreover, as the campaigns are organised individually
by each canton, it is difficult to make generalisations
based on the other cantons’ experience and statistics.
The aim of this study was (i) to compare the sociode-
mographic characteristics of a population of vaccinated
and unvaccinated undergraduate female healtcare stu-
dents in the Geneva canton, (ii) to define the reasons for
not having undergone vaccination in the latter group,
and (iii) to compare the reasons for non-vaccination to
those found in other Swiss cantons.
Material and methods
Population
Recruitement of the study participants took place from
January to November 2017 at the Medical school and at
the School of Health Sciences of the Medical University
of Geneva, located in the city of Geneva, Switzerland.
Women aged 18–31 years, currently attending either
Medical School to obtain a medical doctor degree or the
School of Health Sciences in Geneva to obtain a nurse
or midwife degree, were invited to participate in the
study.
Study design
This study has been carried out as a nested, observa-
tional study within a larger trial evaluating the HPV
vaccine’s effectiveness by analyzing the HPV prevalence
using a cervico-vaginal self-sampling method [12].
Announcements about the study were given by
previously-informed professors teaching classes at the
School of Health Sciences and at the Medical School in
Geneva. An email was also sent by the study investiga-
tors to the students prior to their recruitement. After
having delivered a short presentation about the HPV
infection and the project’s design, the study investigators
distributed the kits to those students who expressed an
interest to participate in the study. The kits contained a
cotton swab for HPV self-sampling (ClassiqSwab,
COPAN, Brescia, Italy), illustrated instructions on how
to use the swab for self-sampling, an informed consent
form, an explanatory document about the HPV infection
and a questionnaire on sociodemographics and their
reasons of non vaccinated choice. Each kit also con-
tained an identification number, to which the partici-
pants could refer to obtain their HPV test results. The
students were given 1 week to return the kit and the
questionnaire to the study investigators. The results of
the HPV analysis were given to the students by a
designated study investigator upon request.
The questionnaire which women were invited to
complete in order to fulfill the aim of this study included
questions about the HPV vaccination uptake or
non-uptake, the participants’ knowledge and attitudes
over the HPV vaccination, their sexual behavior and
country or Swiss canton of origin.
Sample size
The sample size was calculated based on the primary
outcome of the main study [12]. It was obtained based
on an estimated prevalence of 6% of HPV 16/18 infec-
tion in the Swiss population aged less than 30 years. A
total of 400 specimens were needed to detect about an
85% reduction in HPV 16/18 prevalence (prevalence of
0.9% in the vaccinated population), given an 80% power
and a two-sided significance level of 95%. We therefore
estimated that a sample size of 400 women would be
adequate for the analyses.
Statistical analyses
Statistical analyses were run using STATA 13. The
normality of the distribution was tested by the
Kolmogorov-Smirnov test. Descriptive statistics and
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frequencies were analysed for all variables. The T-test
and Chi square test were used for the descriptive
statistics and for the comparaison between variables.
A p value of less than 0.05 was considered as statisti-
cally significant.
Ethical approval
The study protocol was approved by the ethical cantonal
board in Geneva (Commission Cantonale d’Ethique et
de la Recherche – CCER) with the identification number
15–357. All participants signed an informed consent
form prior to taking part in the study. The trial was
registered under cliniclatrials.gov with the identifiers:
NCT03474211.
Results
Sociodemographic and clinical characteristics
Out of 500 kits distributed, a total of 409 were given
back, thus obtaining a response rate of 81.8% (409/500).
Among the 409 participants included in the study, 55%
of them (225/409) were enrolled in Medical School while
45% (184/409) of them attended the School of Health
Sciences. A total of 46% of the study participants
reported their vaccination status based on their own
personal notion, without verifying such data on their
vaccination booklet. Women coming from the Geneva
canton were more represented in the vaccinated (71.1%,
202/284) than in the nonvaccinated group of partici-
pants (59.2%, 74/125), whereas women coming from
other Swiss cantons, who were grouped together with
women coming from other countries (France, Portugal,
Spain ect..) were more represented in the nonvaccinated
group (40.8%, 51/125) than in the vaccinated one
(28.9%, 82/284, p = 0.017). We found that only 2.8% (8/
284) of vaccinated women were infected by the HPV
strains 6, 11, 16 and 18, while up to 11% (17/125) of the
unvaccinated participants were infected by these same 4
strains. The participants’ sociodemographic and clinical
characteristics are reported in Table 1.
Beliefs regarding the importance of the HPV vaccination
Overall, 91.9% (261/284) of the vaccinated women
believed that the HPV vaccination was as important as
other vaccinations, while only 48.8% (61/125) of the
unvaccinated participants believed that the HPV vaccin-
ation was as important as the others (p < 0.001). A total
of 4.6% (13/284) and 0.8% (1/125) vaccinated and unvac-
cinated women, respectively, believed that the HPV
vaccination was more important than other types of vac-
cination. There were 3.5% (10/284) and 50.4% (63/125)
of vaccinated and unvaccinated women, respectively,
who believed that the HPV vaccination was less import-
ant than others. The participants’ perceptions of the im-
portance of the HPV vaccination are reported in Table 2.
Association between opinion on the HPV vaccination and
sociodemographics characteristics
Among unvaccinated participants, the proportion of
women who believed that the HPV vaccination was less
important than others decreased as the women’s age
Table 1 Sociodemographic characteristics and HPV test results
of the study population
Variable vaccinated unvaccinated p value
n=284 n=125
n % n %
Age, y
Mean 22.5
SD (±) 2.9
21.9
SD (±) 2.6
0.16
< 20 110 38.7 50 40 0.03#
20-23 101 35.6 57 45.6
> 23 73 25.7 18 14.4
Origin 0.017
Geneva 202 71.1 74 59.2
Other* 82 28.9 51 40.8
Tobacco smoking 0.31
Yes 53 18.7 27 21.6
No 231 81.3 98 78.4
Age at your first sexual
intercourse, mean (y)
17.1
SD (±) 2.4
17
SD (±) 2.8
0.14
Total number of sexual partners
Mean 5.3
SD (±) 1.26
5.1
SD (±) 1.33
0.42
None 10 3.5 4 3.2 0.98
≤ 5 135 47.5 60 48
> 5 139 48.9 61 48.8
Use of condoms 0.6
Never/sometimes 142 50 66 52.8
Often/always 142 50 59 47.2
HPV prevalence
Types 6, 11, 16, 18 8 2.8 17 11 0.0002
Other HR and LR
HPV types
41 14 25 20 0.12
Abbreviations: HPV Human Papillomavirus, y years, N number, HR high risk HPV,
LR low-risk HPV
*Includes women coming either from other Swiss cantons or from other countries
#p value in boldface are statistically significant
Table 2 Participants’ beliefs about the HPV vaccination
In general, do you think
that HPV vaccination is a
vaccination:
Vaccinated Unvaccinated P value
N % N %
More important than others 13 4.60 1 0.80 < 0.001#
Less important than others 10 3.50 63 50.40 < 0.001
As important as the others 261 91.90 61 48.80 < 0.001
Abbreviations: HPV Human Papillomavirus, N number
#p value in boldface are statistically significant
Amadane et al. Archives of Public Health           (2019) 77:29 Page 3 of 6
increased (62% of the < 20 years group (31/50), 45.6% of
the 20–23 years (26/57), 38.9% of the > 23 years (7/18);
p = 0.35). On the contrary, the proportion of women
who believed that the HPV vaccination was either more
than or as important as other vaccinations increased
with the women’s age (< 20 years: 38% (19/50); 20–23
years: 54.4% (31/57); > 23 years: 61.1% (11/18); p = 0.07).
Association between opinion about the HPV vaccination
and condom use
Among unvaccinated participants who believed that the
HPV vaccination was less important (50.4%; 63/125), 57.1%
of them (36/63) used the condom sometimes/never,
whereas 42.9% (27/63) of them used it often/always.
Among women who considered the HPV vaccination as/
more important than other vaccinations (49.6%; 62/125),
51.2% (32/62) used the condom often or always, while
48.8% (30/62) used it sometimes/never. The association be-
tween the participants’ opinion about the HPV vaccination
and their frequency of condom use is reported in Fig. 1.
Reasons for not having been vaccinated
A total of 41.6% (52/125) of the unvaccinated women
did not give any information or did not know why they
had not been vaccinated. Among women who gave a
reason for not having been vaccinated (58.4%, 73/125),
the reported reasons included: fear of side effects (21.6%,
27/125); parents being against the vaccination, either in
general or the HPV-one (14.4%; 18/125); the physician
in private practice being against the HPV vaccination
(8.8%; 11/125); the vaccination not being considered as
useful (2.4%; 3/125); the person being against vaccina-
tions in general (2.4%; 3/125); sexual inactivity (1.6%; 2/
125); insufficient evidence on the vaccine’s efficacy and
side effects (1.6%; 2/125). The reasons for not having
been vaccinated are reported in Table 3.
Discussion
This is the first study to evaluate the acceptability of the
HPV vaccine in Geneva since the introduction of the
HPV vaccination in the canton. Our results revealed that
69.4% of our study population was vaccinated against
HPV, a rate higher than the rest of Switzerland where,
according to the results of a survey conducted in 2016,
only 53.6% of women aged 18–24 years were vaccinated
[13]. Another study conducted in 2014 found that the
French-speaking Swiss regions vaunt a vaccination rate
of 68.1%, which is consistent with the rate found in our
trial [10]. Moreover, a recent systematic review
collecting data from 28 countries pointed out the
heterogeneity of vaccination rates worlwide, varing
from 2.4 to 94.4% [14].
However, Our results reflect a reality in which,
despite the remarkable efforts to reach the optimal
vaccination coverage rate, the resistance to the vac-
cination prevents public health workers from reaching
the optimal coverage rate. When looking at reasons
for non-vaccination, three of them stood out: fear of
side effects (21.6%), parents being against the HPV
vaccination (14.4%) and the physician being against
the vaccination (8.8%). Similarly, in a study including
women aged 18–24 years living in the French-speak-
ing region in Switzerland [10], the main reasons for
not having been vaccinated were: thinking it was too
late (due to either age, sexual activity, or pathological
smear) (52%), fear of side effects (26%), not having
received enough information (19%), being against all
kinds of vaccination (17%) and having discouraging
relatives and friends (15%). Furthermore, a study
Fig. 1 Association between use of condom and opinion about HPV-vaccination among the unvaccinated group of participants
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including 16–20 year-olds living in the Canton of
Vaud [9] revealed a lack of information about the
HPV infection’s natural history and prevention, as
over 70% of the interviewed population felt insuffi-
ciently informed about the disease. Moreover, one of
the issues highlighted by 29% of the physicians work-
ing in private practice in the French-speaking region
of Switzerland [8] was the lack of information and
support brought by their cantons. A recent study
conducted in Switzerland following the first 2 years
after the vaccination’s introduction reported that only
117 cases of Gardasil®-associated side effects were
found among 420′000 vaccine doses. The same study esti-
mated that 93–98% of CIN2+ lesions caused by 16 and 18
genotypes and 46–70% of the CIN2+ lesions caused by
other HPV genotypes could be avoided with vaccination
[15]. Such results, which can be used by public health
workers to improve the future vaccination campaigns,
demonstrate that the lack of information about the HPV
infection and its prevention concerns not only the general
population, but also health professionals.
Concerning the opinion about the importance of
the HPV vaccination, we found that the difference be-
tween vaccinated and unvaccinated women was com-
patible with their immunization status. Over 50.4% of
unvaccinated women considered the vaccination as
less important than other vaccinations, while 91.9% of
vaccinated women considered it as as important as
other vaccinations. Another study carried out in Italy
obtained similar results among women aged 18–21
years old, thus demonstrating that one of the factors
associated with not having been vaccinated was the
lower perception of its benefits [16].
A small majority (51.1%) of our population sample had
been vaccinated between the ages of 15 and 19 years old,
although vaccination for women in this age range was
meant to be a catch-up for those who had missed their
opportunity to be vaccinated in the first place. Knowing
that the moment for the ideal vaccination is before first
sexual intercourse, which in our population took place
at a median age of 17.2 years old, baseline vaccination
for all 15–19 years-olds seems to be a reasonable target
to improve prevention. Nevertheless, the median age
when receiving the first vaccine dose in our study
population was 14.8 years old. The small percentage of
vaccinated women after the age of 20 years old (4.2%) is
not surprising considering that the campaign mainly
targets the younger part of the population. Such results
are in line with those of a study [6] evaluating the age at
the first dose of HPV vaccine in a population of Swiss
women, which found that the vaccination rates were
54.4% for women between aged 15–19 years old, 39.8%
for women aged 11–14 years old, and 5.8% for women
older than 20.
When studying the sociodemographic characteristics
of our population, only nationality was found to be
significantly associed to vaccination status, as a greater
proportion of women coming from Geneva and its sur-
roundings were vaccinated when compared to women
coming from other cantons and countries. Given the
difference of the vaccination campaigns and policies in
other cantons and countries, such finding highlights the
efficacy of the vaccination campaign in the canton of
Geneva, where a particularly active role was played by
the SSJ in public and private schools. Other studies have
confirmed that, when the SSJ was involved in vaccin-
ation campaigns, as is the case in other French-speaking
cantons in Switzerland, such finding resulted in better
vaccination rates than those in the German-speaking
part of Switzerland [9].
One strength of our study was given by the fact that
we chose a population of young, future healthcare pro-
viders, whose opinion is fundamental in the view of
spreading the vaccination uptakein the near future. In
addition, this population sample of young adults has
never been studied in such geographical area.
One limitation of our study was the sample’s relatively
small size, which limited the power of some of our
observations. A selection bias also may have occurred,
as all the participants not only had a high educational
degree but also studied medical and health sciences,
which does not reflect the heterogeneity of the general
population. Additionally, the HPV kits were offered to
the students who proactively expressed an interest to
participate in the study, excluding the girls possibly
having another opinion about the HPV vaccination.
Finally, 46.3% of our participants had not checked their
Table 3 Reasons for not having been vaccinated among
unvaccinated women
Variable n %
No reason given or doesn’t know 52 41.6
Reason given : 73 58.4
Fear of side effects 27 21.6
Parent against HPV vaccination 18 14.4
Physician in private practice
against HPV vaccination
11 8.8
Not considered useful 3 2.4
Against vaccinations in general 3 2.4
No sexual activity 2 1.6
Only 1 sexual partner 2 1.6
No efficacy 2 1.6
Insufficient evidence 2 1.6
Other 3 2.4
Abbreviations: N number, HPV Human Papillomavirus
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vaccination record to answer the questionnaire, an
aspect which may have altered some of the study results.
Conclusion
The suboptimal HPV vaccination rate among our study
population of undergraduate women shows that, despite
the vaccine’s proven efficacy, the coverage rate is still far
from reaching 80%. The majority of vaccinated women
in our study population came from the Geneva Canton,
a finding which further highlights the discrepancies in
vaccination campaigns in the country. Proactive educa-
tion about the HPV infection’s natural history and the
vaccination’s role, to be delievered by the women’s
personal healthcare providers, represents a fundamental
step in increasing the vaccination coverage rate across
the country.
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